An Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Paxalisib (Primary)
- Indications Brain metastases; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Lymphoma; Malignant melanoma; Meningeal carcinomatosis; Rhabdoid tumour
- Focus Pharmacokinetics
- Sponsors Kazia Therapeutics
- 13 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Mar 2023 Planned End Date changed from 1 Aug 2022 to 1 Mar 2023.
- 08 Mar 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Mar 2023.